Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Double-blinded, Randomized, Placebo-controlled, Intra-individual Comparison, Phase Ib Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intra-dermal Injections of DLX105 Into Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris

NCT01595997 is registered in ClinicalTrials.gov with Delenex Therapeutics AG as lead sponsor.

NCT NCT01595997
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01595997 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Double-blinded, Randomized, Placebo-controlled, Intra-individual Comparison, Phase Ib Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intra-dermal Injections of DLX105 Into Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris
Lead sponsor
Delenex Therapeutics AG
Phase
Phase 1/2
Overall status
Completed
Start date
February 29, 2012
Completion date
October 31, 2012
Enrollment
20 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

mild-to-moderate psoriasis vulgaris